1. Home
  2. MMD vs ELDN Comparison

MMD vs ELDN Comparison

Compare MMD & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStay MacKay DefinedTerm Municipal Opportunities Fund

MMD

MainStay MacKay DefinedTerm Municipal Opportunities Fund

HOLD

Current Price

$15.24

Market Cap

280.2M

Sector

Finance

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$3.95

Market Cap

291.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMD
ELDN
Founded
2012
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.2M
291.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
MMD
ELDN
Price
$15.24
$3.95
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
55.3K
1.6M
Earning Date
01-01-0001
05-12-2026
Dividend Yield
4.88%
N/A
EPS Growth
N/A
30.67
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.37
$1.35
52 Week High
$15.82
$4.60

Technical Indicators

Market Signals
Indicator
MMD
ELDN
Relative Strength Index (RSI) 55.33 64.19
Support Level $15.14 $2.45
Resistance Level $15.40 $4.60
Average True Range (ATR) 0.16 0.22
MACD 0.02 -0.01
Stochastic Oscillator 69.50 76.74

Price Performance

Historical Comparison
MMD
ELDN

About MMD MainStay MacKay DefinedTerm Municipal Opportunities Fund

NYLI MacKay DefinedTerm Muni Opportunities Fund is a USA-based diversified closed-end management investment company. The fund's investment objective is to seek current income exempt from regular U.S. Federal income taxes as well as total return. The company predominantly invests in municipal bonds, the interest on which is, in the opinion of bond counsel to the issuers, generally excludable from gross income for regular U.S. Federal income tax purposes.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

Share on Social Networks: